EBR Systems, Inc. (ASX:EBR), a Silicon Valley-based developer of the world's only wireless cardiac pacing device for heart failure, has disclosed that its senior management team will host an investor webinar on Tuesday, 10 November 2026 at 12:00pm AEDT to discuss the company's Q3 2026 results.

Key Points

  • EBR Systems' senior management will host an investor webinar on 10 November 2026 at 12:00pm AEDT (9 November at 5:00pm PST) to discuss Q3 2026 results
  • EBR Systems is the developer of the world's only wireless cardiac pacing device for heart failure, using its patented WiSE technology
  • The WiSE technology eliminates the need for coronary sinus leads in heart failure patients requiring Cardiac Resynchronisation Therapy (CRT)
  • The WiSE device implant is roughly the size of a large grain of rice and delivers endocardial stimulation of the left ventricle

Investor Webinar Timing and Format

EBR Systems' senior management team will host the investor webinar on Tuesday, 10 November 2026 at 12:00pm Australian Eastern Daylight Time, which corresponds to Monday, 9 November 2026 at 5:00pm Pacific Standard Time. The webinar is focused on the company's Q3 2026 results. According to the filing, registrants will receive a confirmation email containing information about joining the webinar following completion of their registration. The company's disclosure was authorised for release by the EBR Systems Routine Disclosure Committee, a committee of the Board of Directors.

WiSE Technology and Cardiac Pacing Application

EBR Systems' patented Wireless Stimulation Endocardially (WiSE) technology is described in the filing as the world's only wireless, endocardial pacing system in clinical use for stimulating the heart's left ventricle. The technology was developed to eliminate the need for cardiac pacing leads, which the filing identifies as historically the major source of complications, effectiveness and reliability issues in cardiac rhythm disease management. The WiSE system features a novel cardiac implant approximately the size of a large grain of rice. The filing notes that WiSE is an investigational device in most markets and is currently only available for sale in the United States.

Company Profile and Product Scope

EBR Systems is headquartered in Santa Clara, California, and is listed on the ASX through CHESS Depositary Interests (CDIs). The company's initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac Resynchronisation Therapy. According to the filing, future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications. The company's CDIs are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 for offers or sales made outside the United States.